About Northfield
We are a leader in developing a hemoglobin-based oxygen-carrying red blood cell substitute. The initial indication we are seeking for our product PolyHeme® is the treatment of life-threatening hemoglobin levels when blood transfusion is indicated but red blood cells may not be available, appropriate or acceptable. PolyHeme® is a solution of chemically modified human hemoglobin that requires no cross-matching and is therefore compatible with all blood types. It has an extended shelf life in excess of 12 months.
|
|
|
51-200 employees
View all Northfield employees
|
|
Biotechnology
|
|
US
|
|
1994
|
Northfield Alternatives
Frequently Asked Questions about Northfield
Rob Clark is the CEO of Northfield. To contact Rob Clark email at [email protected].
Northfield Staff Directory
Search Northfield Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
